Segmented EPO Mimetics for Stable EPOR Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current erythropoietin receptor (EPOR) agonists have limited stability, making their production and administration challenging, and they induce anti-EPO antibodies, limiting their therapeutic effectiveness and convenience for patients.
Innovation Solution
Development of smaller, more stable EPO mimetics comprising two peptide chains (Chain A and Chain B) with loop structures and intrachain bridges, which can bind to the EPOR with high affinity and stability, reducing antibody induction and enabling self-administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current EPOR agonists are used, then therapeutic effect is achieved, but stability is limited making production and administration challenging
Solution Approach 1:
The EPO molecule is divided into two separate peptide chains (Chain A and Chain B), each containing a loop structure with intrachain bridges. This segmentation allows each chain to be more stable and easier to manufacture independently while maintaining therapeutic effectiveness when combined.
Solution Approach 2:
The invention creates a composite structure by covalently linking two distinct peptide chains (Chain A and Chain B) through interchain bridges. This composite approach combines the stability benefits of both chains while achieving enhanced overall molecular stability and manufacturability.
2Reliability
If current EPOR agonists are used, then erythropoiesis stimulation is achieved, but anti-EPO antibodies are induced limiting therapeutic effectiveness
Solution Approach 1:
The invention creates simplified copy structures (Chain A and Chain B) that replicate the essential binding functionality of full EPO but with reduced immunogenicity. These peptide chains copy the critical epitopes needed for EPOR binding while having a different overall structure that avoids triggering anti-EPO antibodies.
Solution Approach 2:
The invention extracts only the essential functional portions of EPO needed for EPOR binding and erythropoiesis stimulation, removing the portions that trigger antibody formation. The peptide chains contain minimal sequences necessary for therapeutic effect while excluding immunogenic elements.
3Reliability
If larger EPO molecules are used, then binding affinity is achieved, but self-administration becomes difficult
Solution Approach 1:
By segmenting EPO into two smaller peptide chains, the invention creates molecules that are small enough for convenient self-administration via subcutaneous injection, while maintaining sufficient binding affinity through the optimized loop structures and bridge configurations in each chain.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The EPO mimetics demonstrate enhanced stability and bioavailability, reducing anti-EPO antibody induction and allowing for subcutaneous self-administration, while maintaining therapeutic efficacy comparable to recombinant human EPO.
Implementation Method 1
Each of Chains A and B can contain a loop structure that is defined by an intra-chain bridge covalently linked across the loop
Implementation Method 2
The loop structure can make hydrophobic interactions (e.g., hydrophobic contacts) with the EPO receptor when bound thereto
Data Source
AI summary
The present invention provides mimetics of erythropoietin that bind to the erythropoietin receptor and that are suitable for use in pharmaceutical compositions. The present invention also provides methods of treatment using the mimetics of erythropoietin as well as methods of making the mimetics of erythropoietin.